Arbutus Biopharma Corp. appointed David Hastings as CFO, effective June 11.
Hastings replaces Koert VandenEnden, who was serving as interim CFO of the company.
Previously, Hastings served as the CFO and executive vice president of Incyte Corp., a life sciences oncology company, from 2003 until 2014.
VandenEnden continues to serve as chief accounting officer and will continue to act as the principal accounting officer during the CFO transition to Hastings.
Canada-based Arbutus Biopharma is a biopharmaceutical company that engages in the discovery, development and commercialization of a cure for patients suffering from chronic Hepatitis B virus infection.
